AMAG Pharmaceuticals Competitors and Similar CompaniesClear all
AMAG Pharmaceuticals's competitors and similar companies include Agios Pharmaceuticals, Alexion Pharmaceuticals, TherapeuticsMD and Acorda Therapeutics.
 AMAG Pharmaceuticals AMAG Pharmaceuticals is a pharmaceutical company that develops and delivers medicines across a range of therapeutic areas. |  Agios Pharmaceuticals Agios Pharmaceuticals is a biopharmaceutical company discovering and developing therapeutics for cancer metabolism. |  Alexion Pharmaceuticals Alexion (also known as Alexion, AstraZeneca Rare Disease) is a biopharmaceutical company engaged in therapies for rare diseases. |  TherapeuticsMD TherapeuticsMD is a pharmaceutical company focused on producing generic prescriptions and over-the-counter products for women.
|  Acorda Therapeutics Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders. | |
Founding Date | Founding Date 1981 | Founding Date 2008 | Founding Date 1992 | Founding Date 2008 | Founding Date 1995 |
Type | Type Subsidiary | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Waltham, US HQ | Locations Cambridge, US HQ | Locations Boston, US HQ Frenchs Forest, AU Wien, AT Elsene, BE São Paulo, BR Vaughan, CA Shanghai, CN see more | Locations Boca Raton, US HQ | Locations Ardsley, US HQ Chelsea, US South San Francisco, US Waltham, US |
Employees | Employees 3751% decrease | Employees 53611% increase | Employees 10,6006% increase | Employees 34844% increase | Employees 4742% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) 2.7 b | Valuation ($) 40.3 b | Valuation ($) 18.1 m | Valuation ($) 821 k |
Financial | |||||
Revenue (est.) | Revenue (est.) $327.8m (FY, 2019) | Revenue (est.) $54m (FY, 2025) | Revenue (est.) $6.1b (FY, 2020) | Revenue (est.) $3m (FY, 2025) | Revenue (est.) $117.6m (FY, 2023) |
Cost of goods | Cost of goods $107.2m (FY, 2019) | Cost of goods $6.3m (FY, 2025) | Cost of goods $553.5m (FY, 2020) | Cost of goods N/A | Cost of goods $15.3m (FY, 2023) |
Gross profit | Gross profit ($106.9m) (FY, 2019) | Gross profit $47.7m (FY, 2025) | Gross profit $5.5b (FY, 2020) | Gross profit N/A | Gross profit N/A |
Net income | Net income ($466.5m) (FY, 2019) | Net income ($412.8m) (FY, 2025) | Net income $603.4m (FY, 2020) | Net income ($569k) (FY, 2025) | Net income ($252.9m) (FY, 2023) |
Operating ⚠ | |||||
Products | Products 4 (FY, 2019) | Products N/A | Products 5 (Q1, 2021) | Products N/A | Products N/A |
For sources of this data, please see the company profile
View Company Profiles
Agios Pharmaceuticals
HQ
Cambridge, US
Employees
536↑ 11% increase
Agios Pharmaceuticals is a biopharmaceutical company discovering and developing therapeutics for cancer metabolism.
View companyAlexion Pharmaceuticals
HQ
Boston, US
Employees
10,600↑ 6% increase
Alexion (also known as Alexion, AstraZeneca Rare Disease) is a biopharmaceutical company engaged in therapies for rare diseases.
View companyTherapeuticsMD
HQ
Boca Raton, US
Employees
348↑ 44% increase
TherapeuticsMD is a pharmaceutical company focused on producing generic prescriptions and over-the-counter products for women.
View companyAcorda Therapeutics
HQ
Ardsley, US
Employees
474↓ 2% decrease
Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders.
View company